University of Minnesota. Driven to Discover.
The study of VSV-EBOV hopes to enroll 6,000 health and other frontline workers.
The first two phase 1 trials of VSV-EBOV vaccine show good immune responses.
With its Mar 7 launch date, the trial's main goal is to see if ring vaccination can knock down Ebola hot spots.
An international team of experts says, in effect, "Don't be so sure" about Ebola not spreading by air.
The small biotech and the drug giant announced an agreement today.
MSF says the outbreak is not over and calls for rapid response teams for hot spots.
An efficacy trial could start in Liberia in December, according to WHO.
Experts today pushed for new ways to test Ebola treatments, and two groups renewed their urgent pleas for aid.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.